相关实验视频

Updated: Sep 11, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

早期的ctDNA动态为患有扩散阶段小细胞肺癌的患者提供一线治疗的信息

Carmela Ciardullo¹, Luis Tobalina¹, T Hedley Carr²

¹AstraZeneca (United Kingdom), Cambridge, United Kingdom.

Clinical cancer research : an official journal of the American Association for Cancer Research

|August 11, 2025

概括

在广泛的小细胞肺癌 (ES-SCLC) 中监测循环瘤DNA (ctDNA) 显示了早期治疗反应,并预测了复发. ctDNA动态为治疗疗效和ES-SCLC潜在的分子复发提供了一个敏感的标记.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断
基因组学就是基因组学.

背景情况:

小细胞肺癌 (SCLC) 是一种高度攻击性的恶性瘤,治疗选择有限,患者的治疗结果不佳.
目前的SCLC监测方法可能不能准确地反映治疗反应或预测复发.
循环瘤DNA (ctDNA) 分析为疾病监测提供了一个有希望的,最少侵入性的方法.

研究的目的:

评估ctDNA对监测疾病进展和评估广泛阶段SCLC (1L ES-SCLC) 的第一线治疗疗效的有用性.
为了将ctDNA动态与1L ES-SCLC患者的治疗反应和临床结果相关联.

主要方法:

该TAZMAN试验招募了31名患有1LES-SCLC的患者,接受标准化疗加杜尔瓦卢马布.
来自27名患者的血样本 (n=228) 用液体活检方法分析了体质突变和拷贝数异常.
分析考虑了克隆性血液形成 (CH) 突变,以区分它们与瘤衍生的变化.

主要成果:

基线ctDNA检测到96.3%的患者体质变化,主要是TP53和RB1基因.
早期治疗的ctDNA动态显示,变异性等位基因频率 (VAF) 显著降低,这表明了最初的化学敏感性.
低于检测极限的ctDNA水平预测了更长的治疗持续时间和预期的成像前复发,突出了ctDNA的敏感性.

结论:

早期的ctDNA动态为1L ES-SCLC的治疗疗效和潜在的分子复发提供了宝贵的见解.
ctDNA分析可以加强治疗监测,并可能指导停止无效治疗.
使用扩展下一代测序 (NGS) 面板进行更大规模的研究是有必要的,以充分阐明ctDNA在SCLC管理中的作用.

更多相关视频

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...